Upping expectations, Sanofi makes its case on why Dupixent will go on to $14.5B in peak sales — whatever Eli Lilly may have on its mind
Over the weekend, Eli Lilly laid out some solid Phase III reasons why the pharma giant thinks it can take on Regeneron and Sanofi’s Dupixent on the severe atopic dermatitis front. But no one at Sanofi appears to have been listening very seriously.
Monday night the Paris-based multinational laid out its case for why Dupixent will be one of the biggest drug franchises in biopharma history. And Sanofi CEO Paul Hudson made that very clear by promising their drug will go on to marketing history with about $14.5 billion in peak sales.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.